Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11921840 | 0.82 | HTT (0.33) | HTTSMN1; SMN2 | |
| SCHEMBL27726657 | 0.82 | HMGCR (0.35) | TSHRHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL20937487 | 0.80 | HPGD (0.32) | — | |
| SCHEMBL25933609 | 0.78 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL13105063 | 0.77 | HMGCR (0.35) | TSHRHMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL24535254 | 0.77 | PTPN1 (0.30) | STAT3PTPN1 | |
| SCHEMBL13877935 | 0.77 | ALOX15 (0.32) | STAT3PTPN1ALOX15TSHR | |
| SCHEMBL11235250 | 0.77 | PTPN1 (0.30) | STAT3PTPN1 | |
| SCHEMBL9004553 | 0.75 | STAT3 (0.32) | STAT3ALOX15TSHR | |
| SCHEMBL28568122 | 0.75 | PTPN1 (0.46) | STAT3PTPN1ALOX15TSHRHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-01-21 | — | — | US | disclosed |
| US-10023588-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-17 | — | — | US | disclosed |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2018-07-03 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | STAT3 4734/4885PTPN1 2938/4885F2 625/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | STAT3 473/4885PTPN1 1645/4885F2 4159/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | STAT3 3812/4885PTPN1 1601/4885F2 4424/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | STAT3 4478/4885PTPN1 3077/4885F2 577/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | STAT3 473/4885PTPN1 1645/4885F2 4159/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | STAT3 2417/4885PTPN1 776/4885F2 1025/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | STAT3 4734/4885PTPN1 2938/4885F2 625/4885 |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | PPOX, DDC, DDO | STAT3 3102/4885PTPN1 4851/4885F2 517/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | STAT3 4734/4885PTPN1 2938/4885F2 625/4885 |
| US-10023588-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | STAT3 473/4885PTPN1 1645/4885F2 4159/4885 |
| US-10010548-B2 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | STAT3 1003/4885PTPN1 668/4885F2 3927/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | STAT3 473/4885PTPN1 1645/4885F2 4159/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | STAT3 2417/4885PTPN1 776/4885F2 1025/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | STAT3 1183/4885PTPN1 1265/4885F2 4470/4885 |
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | PPOX, DDO, DDC | STAT3 3232/4885PTPN1 4866/4885F2 433/4885 |
| US-20230242548-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | STAT3 473/4885PTPN1 1645/4885F2 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.